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Background: Dendritic cells (DC) are the most potent antigen-presenting cells (APC) with the unique ability to activate
naïve T cells and to initiate and maintain primary immune responses. Immunosuppressive and anti-inflammatory stimuli
on DC such as the cytokine IL-10 suppress the activity of the transcription factor NF-κB what results in downregulation
of costimulatory molecules, MHC and cytokine production. Glycoprotein NMB (GPNMB) is a transmembrane protein,
which acts as a coinhibitory molecule strongly inhibiting T cell responses if present on APC. Interestingly, its expression
on human monocyte-derived dendritic cells (moDC) is dramatically upregulated upon treatment with IL-10 but also by
the BCR-ABL tyrosine kinase inhibitors (TKI) imatinib, nilotinib or dasatinib used for the treatment of chronic myeloid
leukemia (CML). However, the molecular mechanisms responsible for GPNMB overexpression are yet unknown.
Results: The immunosuppressive cytokine IL-10 and the BCR-ABL TKI imatinib or nilotinib, that were examined here,
concordantly inhibit the PI3K/Akt signaling pathway, thereby activating the downstream serine/threonine protein kinase
GSK3ß, and subsequently the microphthalmia-associated transcription factor (MITF) that is phosphorylated and
translocated into the nucleus. Treatment of moDC with a small molecule inhibitor of MITF activity reduced the expression
of GPNMB at the level of mRNA and protein, indicating that GPNMB expression is in fact facilitated by MITF activation. In
line with these findings, PI3K/Akt inhibition was found to result in GPNMB overexpression accompanied by reduced
stimulatory capacity of moDC in mixed lymphocyte reactions (MLR) with allogeneic T cells that could be restored by
addition of the GPNMB T cell ligand syndecan-4 (SD-4).
Conclusions: In summary, imatinib, nilotinib or IL-10 congruently inhibit the PI3K/Akt signaling pathway thereby
activating MITF in moDC, resulting in a tolerogenic phenotype. These findings extend current knowledge on the
molecular mechanisms balancing activating and inhibitory signals in human DC and may facilitate the targeted
manipulation of T cell responses in the context of DC-based immunotherapeutic interventions.
Keywords: Dendritic cells, Coinhibitory receptor, Glycoprotein NMB, Tyrosine kinase inhibitors, PI3K/Akt signaling
pathway, Microphthalmia-associated transcription factorBackground
Pathways involved in negative T cell regulation are of great
interest, as on the one hand they can fatally attenuate T
cell responses against cancer cells and on the other hand
do offer an opportunity to develop tolerance-inducing
strategies in Graft-versus-host disease (GvHD) and auto-
immune diseases [1,2].
DC are the most powerful APC and play a key role in
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unless otherwise stated.of costimulatory and/or coinhibitory molecules [3]. After
stimulation by TLR ligands, TNF, IFN-γ or T cell signals,
DC undergo a complex maturation process, express costi-
mulatory molecules and migrate into lymph nodes where
they prime naive T cells. In contrast, in the absence of acti-
vating signals and/or in the presence of immunosuppres-
sive and anti-inflammatory factors like IL-10, TGF-β,
prostaglandin D2 (PGD2) or corticosteroids, DC achieve a
tolerogenic phenotype mediated by the expression of mol-
ecules that suppress T cell activation and induce T cell an-
ergy [3,4]. Due to their unique ability to induce specific T
cell responses DC are employed in immunotherapeutictral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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term clinical responses [5-7].
At the same time, targeted therapies withTKI have signifi-
cantly improved treatment of cancer with imatinib being
the first to be established in the treatment of chronic mye-
loid leukemia (CML). It efficiently blocks the pathologically
activated c-ABL tyrosine kinase activity of the BCR-ABL fu-
sion oncogene [8-10]. Nilotinib and dasatinib, second-
generation TKI initially developed for the treatment of pa-
tients who are resistant or intolerant to imatinib, are now
used as first-line therapy [11-13]. Besides c-ABL, these TKI
significantly inhibit c-Kit and PDGFR tyrosine kinase activ-
ity and imatinib therefore is being used against other malig-
nancies including gastrointestinal stromal tumors. However,
little is known about their effects on immune cells.
Recently, the type I transmembrane receptor GPNMB
(Glycoprotein NMB, DC-associated transmembrane pro-
tein (DC-HIL), osteoactivin), expressed on APC, was shown
to strongly inhibit responses of CD4+ and CD8+ T cells by
binding to its ligand syndecan-4 (SD-4) [14-18]. We previ-
ously demonstrated that primary human moDC moderately
express GPNMB and dramatically upregulate its expression
if generated in the presence of the cytokine IL-10, a main
suppressor of cellular immunity, but notably also when ex-
posed to imatinib, nilotinib or dasatinib [19,20].
Here we aimed to elucidate the molecular switch of
cellular signaling upon inhibition of moDC. Our in vitro
study revealed concordant inhibition of PI3K/Akt signal-
ing by IL-10 or the BCR-ABL TKI imatinib and nilotinib
that resulted in dephosphorylation and activation of
glycogen synthase kinase-3-ß (GSK3ß) and subsequent
phosphorylation and translocation of the transcription
factor MITF [21]. Moreover, treatment of moDC with
the small molecule inhibitor of the MITF molecular
pathway ML329 [22] reduced the expression of GPNMB
at the level of mRNA and protein, indicating that
GPNMB expression is in fact facilitated by MITF
activation.
The basic helix-loop-helix leucine zipper transcription
factor MITF, which was initially described as a key regula-
tor for melanocyte differentiation, comprises at least eight
isoforms differentially expressed within various cell types
[21,23]. However, its expression pattern and functional
role in hematopoietic and blood cells was so far unknown.
Finally, PI3K/Akt inhibition was found to result in
GPNMB overexpression accompanied by reduced stimula-
tory capacity of moDC in mixed lymphocyte reactions
(MLR) with allogeneic T cells that could be restored by
addition of the T cell ligand SD-4, demonstrating the func-
tional relevance of the elucidated signaling mechanism.
Taken together, our data indicate that the therapeutically
used BCR-ABL TKI imatinib and nilotinib exert immuno-
suppressive effects in primary moDC by interfering with
pathways involved in IL-10 receptor signaling andactivation of MITF. These findings extend the current
knowledge about the molecular mechanisms balancing be-
tween activating and inhibitory signals in DC and, thus,
could help to avoid impaired immune responses due to
TKI treatment. In addition, manipulation of the relevant
signaling cascades and/or GPNMB expression or function
may constitute a promising strategy in combinatory ap-
proaches using BCR-ABL TKI and DC-based immunother-
apy and may also allow for manipulation of T cell responses
in GvHD.
Results
PI3K/Akt-Inhibition upregulates GPNMB expression in
moDC
Besides BCR-ABL, imatinib, nilotinib and dasatinib in-
hibit a variety of other kinases including c-Kit [24]. The
main downstream signaling cascades are the Ras/Erk-
and the PI3K/Akt pathway. Evidence that IL-10 receptor
signaling could be affected by these clinically used TKI
is deduced from the observation in mouse DC that IL-
10 blocks Akt phosphorylation, and inhibitors of PI3K
effectively suppress the activation of Akt and subsequent
IκB kinase (IKK) and nuclear factor-κB (NF-κB) [25].
In our first experiments, the relevance of these pathways
in (up-) regulation of immune repressive GPNMB in hu-
man DC was examined. Therefore, we generated imma-
ture moDC in vitro from CD14+ monocytes of healthy
donors, incubated with the PI3K inhibitor LY294002, Akt
inhibitor MK2206, Erk inhibitor FR180204 or imatinib or
nilotinib as a control. GPNMB expression was determined
by qRT-PCR and FACS analysis at day 7 of cell culture.
Consistent with our previous findings, incubation with
BCR-ABL TKI imatinib or nilotinib from the first day of
culturing resulted in a marked increase of GPNMB
steady-state mRNA concentrations (Figure 1A) and cell
surface protein (Figure 1B) on CD209+ (DC-SIGN+)
moDC. Interestingly, treatment of cells with 125–1000
nM Akt inhibitor or 500–1000 nM of PI3K inhibitor also
led to upregulation of GPNMB expression (Figure 1A, B
and Additional file 1: Figure S1). In contrast, inhibition of
the Erk-pathway by FR180204, c-Raf inhibitor 553008 or
MEK1/2 inhibitors U0126 and PD0325901 did not have
any significant effect on GPNMB expression (Figure 1A
and B or data not shown). In response to triggering TLR4
signaling by lipopolysaccharide (LPS), Akt is phosphory-
lated rapidly through PI3K [26]. In accordance with this
mechanism and our previous findings [20], stimulation of
moDC with LPS resulted in downregulation of GPNMB
expression and compensated nilotinib-induced upregula-
tion of GPNMB cell surface protein (Figure 1C).
Immunophenotyping using flow cytometry (FACS) re-
vealed that moDC treated with nilotinib or Akt inhibitor
consistently retained a more CD14+ phenotype and ex-
hibited reduced expression of the DC marker CD1a as
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hibition of full cellular differentiation. Other typical sur-
face markers necessary for T cell activation, such as
CD80, CD86 or the DC-specific adhesion receptor DC-
SIGN (CD209), were not consistently affected by the dif-
ferent treatments (data not shown). Administration of
300 nM Akt inhibitor slightly increased the percentage
of dead cells by an average of 3.5% in comparison with
untreated cells (data not shown).
Combined, these experiments demonstrate the func-
tional involvement of the PI3K/Akt pathway in the regu-
lation of the expression of the inhibitory molecule
GPNMB in moDC.
The BCR-ABL TKI imatinib and nilotinib or IL-10 inhibit
phosphorylation of Akt in moDC
Recently, we showed that imatinib affects phenotype, cyto-
kine secretion, and T cell stimulatory capacity of moDC
due to the inhibition of NF-κB and Akt signaling pathways
[27]. To analyze the relevance of PI3K/Akt signaling for
the regulation of GPNMB expression, we examined the
protein levels of Akt as well as its phosphorylation status
in moDC by western blotting. To this end, moDC were
generated from different donors, in the presence of ima-
tinib, nilotinib, Akt inhibitor MK2206 or the immunosup-
pressive cytokine IL-10 as a positive control. GM-CSF and
IL-4 activate the PI3K/Akt signaling pathway in mono-
cytes which is critical for differentiation and generation of
immature moDC [28]. To keep this pathway active,
CD209+ purified cells were further incubated for 20 and/
or 40 min under the same cell culture conditions as on
day 0 to restore the initial conditions prior to lysis.
Incubation with imatinib (Figure 2A) or nilotinib
(Figure 2B) resulted in decreased amounts of phosphory-
lated Akt as compared to the respective untreated controls
within the indicated timeframe, while the levels of total
Akt remained unchanged. As shown in Figure 2C MK2206
(Akt-inh., 300 nM) very effectively inhibited Akt phosphor-
ylation after 40 min in moDC. These findings were ap-
proved for IL-10 and TKI with moDC generated from
blood monocytes of an additional donor (Figure 2D and
Additional file 2: Figure S2). Furthermore, western blot ana-
lysis confirmed the FACS data (Figure 1B, C) and revealed a
pronounced increase of GPNMB protein levels upon treat-
ment with imatinib or Akt-inhibitor MK2206 (Figure 2E)
as well as nilotinib or IL-10 (Figure 2F). As shown in
Figure 2G, stimulation of moDC with LPS efficiently
compensated imatinib-induced upregulation of GPNMB.
In line with our previous findings these experiments
indicate that BCR-ABL TKI and the immunosuppressive
cytokine IL-10 concordantly inhibit the phosphorylation
of Akt in immature moDC and suggest that Akt dephos-
phorylation is critically involved in the upregulation of
the inhibitory receptor GPNMB.Imatinib, nilotinib, Akt inhibitor or IL-10 prevent phos-
phorylation of GSK3ß in moDC
A central issue of our study was to elucidate the molecular
switch that facilitates transcriptional activation upon BCR-
ABL TKI- or IL-10-mediated inhibition of cellular signal-
ing in moDC. Accordingly, we focused our further ana-
lyses on proteins that promote gene transcription upon
inhibition by Akt. Such a downstream molecule of the
PI3K/Akt pathway is the serine/threonine protein kinase
GSK3β that phosphorylates a broad range of substrates,
including several transcription factors. When the PI3K/
Akt pathway is active, GSK3β is inhibited as a result of
Akt phosphorylation. Conversely, inhibition of PI3K/Akt
signaling results in dephosphorylation and activation of
GSK3β [29,30]. Therefore, we next investigated the possi-
bility that the inhibition of Akt by TKI or IL-10 results in
dephosphorylation and thereby activation of GSK3β in
moDC. For the respective western blot analysis a mono-
clonal antibody that detects both isoforms of GSK3 (α, β)
was used. Consistent with the hypothesized mechanism,
we detected substantially lower amounts of phosphory-
lated GSK3β (upper panels, lower band, 46 kDa) in the
samples treated with imatinib (Figure 3A), nilotinib
(Figure 3B) or Akt inhibitor MK2206 (Figure 3C) as
compared to untreated controls. These experiments
were repeated for IL-10 and TKI with moDC generated
from blood monocytes of an additional donor (Figure 3D
and Additional file 3: Figure S3). The phosphorylation
status of GSK3α (Figure 3A-D: upper bands, 51 kDa) as
well as the level of unphosphorylated GSK3β
(Figure 3A-D: lower panels) was not affected by the
treatment of moDC.
These experiments indicate that inhibition of the Akt
signaling pathway by BCR-ABL TKI, MK2206 or IL-10
in developing human moDC results in reduced phos-
phorylation and subsequent activation of GSK3β and
suggest a mechanism, by which inhibition of cell signal-
ing could induce transcriptional activation of immune
inhibitory molecules such as GPNMB.
The transcription factor MITF is expressed in progenitor
cells, leucocytes and primary moDC
Next we aimed to identify the responsible transcription
factor downstream of the PI3K/Akt signaling cascade
which is activated by GSK3β. Interestingly, GPNMB ex-
pression in melanoblasts and osteoclasts was shown to be
dependent on MITF, and in human glioblastoma cells this
transcription factor is activated by PI3K/Akt and GSK3β
signaling [31,32]. However, its expression pattern and
functional role in hematopoietic and blood cells is so far
unknown. Therefore, we first examined the expression of
MITF mRNA in hematopoietic and blood cells by qRT-
PCR. Significant expression was observed only in CD14+





























Figure 1 (See legend on next page.)
Gutknecht et al. Cell Communication and Signaling  (2015) 13:19 Page 4 of 15
(See figure on previous page.)
Figure 1 PI3K/Akt-inhibition upregulates GPNMB gene expression in human moDC. Immature moDC were generated in vitro with GM-CSF
and IL-4 alone (4/GM) or with additional TKI (3 μM imatinib or 3 μM nilotinib) or inhibitors of signal transduction (300 nM Akt inhibitor MK2206
(Akt-inh.), 300 nM Erk inhibitor FR180204 (Erk-inh.), 100 nM PI3K inhibitor LY294002 (PI3K-inh.), 20 nM c-Raf inhibitor 553003 (c-Raf-inh.)) and analyzed
for GPNMB expression. Exemplary results from at least three independent experiments using different donors are presented. (A) qRT-PCR analysis:
relative level of GPNMB mRNA. The mean (±SD) of duplicate measurements is shown. (B, C) GPNMB protein level of CD209+ moDC (of three different
donors) was analyzed by flow cytometry. Where indicated, maturation of moDC was induced by LPS. Data were analyzed using FlowJo software and
Difference in Median Fluorescence Intensity (DMFI) of CD209+ cells is shown in the upper right quadrants. (D) Phenotypic changes of immature moDC
in the absence (4/GM) or presence of nilotinib or Akt inhibitor were analyzed by flow cytometry. Double stainings were performed with monoclonal
antibodies recognizing CD209, CD1a or CD14. DMFI of CD209+ cells is shown in the upper right quadrants.
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T cells no expression of MITF (Figure 4A). In our next set
of experiments, we analyzed MITF mRNA levels in imma-
ture purified CD209+ moDC. As shown in Figure 4B, tran-
scripts were detected in untreated cells as well as in
samples treated with TKI or IL-10. Notably, steady-state
transcript levels increased upon treatment with imatinib,
nilotinib or IL-10 and positively correlated with the
GPNMB mRNA expression in these cells (Figure 4D and
Additional file 4: Figure S4). Interestingly, among the leu-
cocytes analyzed, GPNMB mRNA was detected only in
CD14+ monocytes used for in vitro generation of moDC4/GM                imatinib














Figure 2 The BCR-ABL TKI imatinib and nilotinib or IL-10 inhibit phos
Akt levels and its phosphorylated form in purified immature CD209+ moDC
and IL-4 alone (4/GM) or with additional (A) imatinib (3 μM), (B) nilotinib (3
(10 ng/mL). Indicated time refers to further treatment of cells prior to cell l
analyzed by western blotting. GAPDH served as loading control. Exemplary
donors are presented.(Figure 4C). However, moDC displayed significantly
higher levels of expression than CD14+ cells (Figure 4D).
Next we determined MITF protein expression in puri-
fied CD209+ moDC by western blotting. In line with the
mRNA expression pattern, we observed MITF protein in
all analyzed cell extracts. Multiple bands representing the
various isoforms were detected, of which the most
prominent migrated at approximately 52 and 56 kDa
(Figure 4E). Due to lack of available phosphospecific anti-
bodies for MITF, the phosphorylated and therefore acti-
vated form could only be detected by mobility shift.
Western blotting revealed an additional, slower migrating4/GM                 nilotinib

















phorylation of Akt in human moDC. Western blot analysis of total
(of four different donors). moDC were generated in vitro with GM-CSF
μM), (C) Akt inhibitor MK2206 (Akt-inh., 300 nM) or (D) IL-10
ysis (see Methods). (E-G) GPNMB protein levels in moDC were
results from at least three independent experiments using different
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Figure 3 Imatinib, nilotinib, IL-10 or Akt inhibitor prevent phosphorylation of GSK3ß in human moDC. Western blot analysis of total
GSK3ß and GSK3α, as well as their phosphorylated forms in purified immature CD209+ moDC (of four different donors). moDC were generated
in vitro with GM-CSF and IL-4 alone (4/GM) or with additional (A) imatinib (3 μM), (B) nilotinib (3 μM), (C) Akt inhibitor MK2206 (Akt-inh., 300 nM)
or (D) IL-10 (10 ng/mL). Indicated time refers to further treatment of cells prior to cell lysis (see Methods). GAPDH served as loading control.
Exemplary results from at least three independent experiments using different donors are presented.
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tein of higher molecular weight at approximately 70 kDa
(Figure 4E).
Thus our data show that the transcription factor MITF
is expressed in both CD14+ monocytes (the starting cells
for the in vitro generation of moDC) and primary human
immature moDC.
MITF is phosphorylated in moDC after BCR-ABL TKI or IL-
10 treatment
In a previous study GSK3 was found to phosphorylate
serine 298 of MITF, thereby enhancing the binding to the
tyrosinase promoter [33]. When analyzing MITF protein
in whole cell lysates of moDC by western blotting, the
additional slower migration band was clearly increased
after 20 min in the samples incubated with nilotinib or
IL-10 as compared to the untreated control (Figure 4E:
lanes 2, 6, 7: upper band, approximately 70 kDa). To con-
firm that the shift in mobility was due to phosphorylation,
cell lysates of moDC generated in the presence or absence
of nilotinib were incubated with phosphatase. We found
that such treatment reduced the intensity of the 70 kDa
band (Figure 4E, lane 4) when compared to untreated sam-
ples (Figure 4E, lane 2 and 6), thus confirming that the mo-
bility shift described above was due to phosphorylation ofMITF. To further verify the specificity of the anti-MITF
antibody, the HeLa cell line that reportedly exhibits a
prominent MITF-band of 56 kDa was included as a control
(Figure 4E: lane 8).
Phosphorylated MITF translocates into the nucleus upon
treatment of moDC with imatinib, nilotinib, IL-10 or Akt
inhibitor
MITF contains a nuclear localization signal (NLS) and
was shown to shuttle between cytoplasmic and nuclear
compartments [34]. Therefore, we prepared cytoplasmic
and nuclear extracts of the differently treated in vitro
generated moDC and evaluated the localization of
MITF. Western blot analyses of nuclear extracts revealed
appearance of phosphorylated MITF after 20 to 40 min
in cells generated in the presence of imatinib (Figure 5A:
right panel), nilotinib (Figure 5B: right panel) or Akt in-
hibitor MK2206 (Figure 5C: right panel) indicating nu-
clear translocation in response to these stimuli. These
findings were confirmed for IL-10 and TKI with moDC
generated from blood monocytes of an additional donor
(Figure 5D: right panel). In contrast, in the cytoplasmic
fractions of the respective moDC populations, only
unphosphorylated protein was detected (Figure 5A-D:
left panels).
Figure 4 The transcription factor MITF is expressed in progenitor cells, leucocytes and primary moDC. Immature moDC were generated
in vitro with GM-CSF and IL-4 alone (4/GM) or with additional TKI (3 μM imatinib or 3 μM nilotinib) or IL-10 (10 ng/mL). For the analysis of CD34+
progenitor and blood cells, cell-type specific total RNA was used. qRT-PCR analysis: (A, B) relative level of MITF and (C, D) GPNMB mRNA. The mean
(±SD) of duplicate measurements is shown. (E) MITF protein level and phosphorylation status was analyzed by western blotting in two different donors
(lanes 1–4 and lanes 5–7, respectively). Phosphorylated MITF was detected by mobility shift (slower migrating band at 70 kDa). Western blotting
revealed an additional, slower migrating band that supposedly represents the phosphorylated protein of higher molecular weight of approximately
70 kDa. “+ phosphatase”: cell lysates were incubated with phosphatase. GAPDH served as loading control. Exemplary results from at least three
independent experiments using different donors are presented.
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phosphorylation of transcription factors. In our experi-
ments, the phosphorylated MITF band disappeared
between 40 and 60 min as shown exemplary for nilotinib
treated cells (Figure 5E: right panel).Taken together, our results show for the first time that
the transcription factor MITF is phosphorylated and
translocated into the nucleus upon inhibition of the
PI3K/Akt signaling cascade by clinically used BCR-ABL
TKI or the immunosuppressive cytokine IL-10 in moDC.




























Figure 5 (See legend on next page.)
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Figure 5 Upon treatment of moDC with imatinib, nilotinib, IL-10 or MK2206, MITF translocates into the nucleus. Western blot analysis of
MITF level and phosphorylation status in the cytoplasmic or nuclear fraction of purified immature CD209+ moDC. moDC were generated in vitro with
GM-CSF and IL-4 alone (4/GM) or with (A) imatinib (3 μM), (B) nilotinib (3 μM), (C) Akt inhibitor MK2206 (Akt-inh.; 300 nM) or (D) IL-10 (10 ng/mL).
(E) Cells were treated with nilotinib (3 μM). Indicated time refers to further treatment of cells prior to cell lysis (see Methods). GAPDH served as loading
control. Exemplary results from at least three independent experiments using different donors are presented.
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pression of inhibitory molecules such as GPNMB.
MITF regulates GPNMB expression in moDC
To directly verify the existence of a functional link between
MITF and GPNMB expression in moDC, we used the
small molecule inhibitor of MITF activity ML329 [22]. To
that end, moDC were generated with or without IL-10 in
the presence of ML329 or the solvent DMSO alone or
CID-5951923 (KLF5 inhibitor) as controls. Importantly,
treatment of cells with up to 2000 nM ML329 did neither
alter their typical phenotype nor induce apoptosis asC
A
Figure 6 MITF-Inhibition decreases GPNMB gene expression in moDC
(4/GM) with or without IL-10 and additional MITF inhibitor ML329 (MITF-inh
control and analyzed for GPNMB expression. (A, B) qRT-PCR analysis: relativ
is shown. (C) GPNMB protein levels were analyzed by western blotting. GA
independent experiments using different donors are presented.analyzed by immune phenotyping and Annexin-V/PI
staining (data not shown). As shown in Figure 6A (and
Additional file 5: Figure S5), incubation with increasing
amounts of ML329 led to a gradual decline of the basal
GPNMB mRNA levels to an average of ~30% with 2000
nM ML329 as compared to the DMSO or CID-5951923
control. Remarkably, even in the samples treated with
IL-10, where GPNMB was strongly upregulated, mRNA
levels were significantly reduced to an average of ~13% with
2000 nM ML329 (Figure 6B and Additional file 5: Figure
S5). Decrease of GPNMB at the protein level was con-
firmed by western blot analyses for moDC generated withGPNMB
GAPDH
B
. moDC were generated in vitro with GM-CSF, IL-4 and DMSO alone
.; 600 nM - 2000 nM) or KLF5 expression inhibitor CID (2000 nM) as
e level of GPNMB mRNA. The mean (±SD) of duplicate measurements
PDH served as loading control. Exemplary results from at least three
Gutknecht et al. Cell Communication and Signaling  (2015) 13:19 Page 10 of 15or without IL-10 and treated with 1000 nM and 2000 nM
ML329 (Figure 6C). Moreover, decrease of cell surface pro-
tein on moDC generated with imatinib or nilotinib and
treated with 2000 nM ML329 was seen in FACS analyses
(Additional file 6: Figure S6).
In summary, these experiments demonstrate that
GPNMB expression in moDC is mediated by the tran-
scription factor MITF as endpoint of the (inhibited)
PI3K/Akt pathway.
Inhibition of the PI3K/Akt pathway results in reduction of
moDC T cell stimulatory capacity that is restored by
soluble SD-4
We have previously shown that GPNMB upregulation upon
exposure to imatinib, dasatinib or nilotinib results in signifi-
cantly reduced T cell stimulatory capacity of moDC [20]. To
confirm the functional relevance of Akt inhibition, we per-
formed T cell proliferation (MLR) assays. For this reason,
immature moDC exposed to MK2206 or imatinib during
development were cultured with allogeneic peripheral blood
mononuclear cells (PBMC) for 5 days and then incubated
with 3H-thymidine. Treatment with Akt inhibitor or ima-
tinib resulted in significantly reduced capacity to stimulate
proliferation of allogeneic T cells to an average of ~50% or
~60%, respectively. (Figure 7 and Additional file 7: Figure
S7). Chung et al. previously reported SD-4 to be the T cell
ligand through which GPNMB mediates its negative co-
regulatory function [15-18]. Therefore, we assessed the spe-
cific role of GPNMB upregulation upon MK2206 treatment
by addition of recombinant ligand SD-4. As demonstratedFigure 7 Akt inhibition reduces the capacity of human moDC to indu
alone (4/GM) or with imatinib (3 μM) or Akt inhibitor MK2206 (300 nM) we
concentration (0.0 μg/mL - 20 μg/mL) of blocking soluble recombinant T c
control. T cell proliferation was measured by [3H]thymidine incorporation. C
measurements is shown. Exemplary result from three independent experimin Figure 7, blockade of endogenous SD-4 by addition of in-
creasing amounts of soluble SD-4 restored the capacity of
MK2206 treated moDC to stimulate proliferation of T cells,
while an irrelevant recombinant protein (Klotho β) had no
effect (Figure 7 and Additional file 7: Figure S7).
These experiments confirm that targeted inhibition of
Akt signaling tunes the development of primary moDC
towards a suppressive phenotype and demonstrate that
upregulation of GPNMB is critically involved in the in-
hibition of DC function.
Discussion
Ex vivo generated and manipulated immunogenic DC
are used in anti-cancer vaccines in experimental and
clinical studies [35]. On the other hand, so-called tolero-
genic DC are considered an interesting alternative to
conventional immunosuppressive therapies since it has
been proven in animal models that their application pre-
vents rejection of transplanted organs. Currently, tolero-
genic DC are also tested in patients with GvHD and in
animal models of autoimmune diseases [36-41].
The in vitro generation of DC from two specific precur-
sor populations is well established: monocytes and CD34+
stem cells. However, the usage of primary moDC is advan-
tageous as they are simple to generate in adequate numbers
and capable of inducing potent specific T cell responses
[42,43]. Adoptive immunotherapy using this cell type for
cancer treatment induces remarkable response rates and in
clinical studies has shown to improve survival even in pa-
tients suffering from advanced disease [44-48].ce T cell responses. moDC generated in vitro with GM-CSF and IL-4
re used as stimulators in MLR with allogeneic T cells. Increasing
ell ligand SD-4 were added with recombinant Klotho β serving as
CPM = corrected counts per minute. The mean (±SD) of quadruple
ents using different donors is presented.
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geted therapies have significantly improved treatment of
cancer. One fascinating example is the introduction of
BCR-ABL TKI to CML treatment. However, discontinu-
ation of imatinib results in a relapse rate in about 50% of
patients [49]. Combination of targeted therapy and im-
munotherapy, with the goal to eradicate minimal residual
disease is therefore moving into the focus of interest. Es-
sential for the application of such combinatory approaches
certainly is to analyze the influence of the respective TKI
on cellular signal transduction in immune cells.
Depending on the micro milieu, DC can be found in dis-
tinct differentiation stages: immature, mature or semi-
mature. Numerous factors induce and/or regulate DC
maturation, of which TLR ligands are the most prominent.
TLR signaling leads to phosphorylation of inhibitory IκB
proteins by activated IKK and the subsequent release of
NF-κB transcription factors, which translocate to the nu-
cleus to induce expression of pro-inflammatory target
genes [50]. Ozes et al. have demonstrated that Akt, acti-
vated by TNF, mediates IKK phosphorylation and subse-
quent NF-κB activation [51]. Simultaneously, activated
Akt inhibits GSK3β by phosphorylation at serine 9. It was
proposed, if Akt is inactive, that the p105 precursor of the
NF-κB p50 subunit is stabilized through phosphorylation
by GSK3β, thus preventing formation of functional active
NF-κB [52].
Previously, we have established that exposure of hu-
man CD14+ peripheral blood monocytes to therapeutic
concentrations of imatinib during differentiation into
moDC affects their phenotype, cytokine secretion, and T
cell stimulatory capacity due to inhibition of NF-κB and
Akt signaling pathways [27]. Furthermore, we have dem-
onstrated that IL-10 prevents nuclear translocation,
DNA binding and TLR-induced nuclear expression of
the NF-κB family members c-Rel and Rel-B as well as
IRF-3 and IRF-8 as a result of inhibitory effects on the
PI3K pathway [19,53].
In the present study we show for the first time that the
concordant inhibition of the PI3K/Akt signaling pathway
by the clinically used BCR-ABL TKI imatinib or nilotinib,
Akt inhibitor MK2206 or the immunosuppressive cytokine
IL-10 activates the downstream serine/threonine protein
kinase GSK3ß, and subsequently the transcription factor
MITF that is translocated into the cell nucleus. Moreover,
treatment of moDC with the small molecule inhibitor of
the MITF molecular pathway ML329 [22] reduced the ex-
pression of GPNMB at the level of mRNA and protein, in-
dicating that GPNMB expression is in fact facilitated by
MITF activation.
Based on these and previous results, we suggest the fol-
lowing general model for balancing activating and inhibi-
tory signals in primary moDC: the central regulatory
molecules in signal processing are the serine/threoninekinases Akt and GSK3β. Activating signals such as growth
factors or TLR stimulation lead to phosphorylation of Akt
that causes phosphorylation and thereby inhibition of
GSK3β. Inactive GSK3β permits the formation of func-
tional members of the NF-κB transcription factor family
that induce the transcription of proinflammatory genes.
By contrast, inhibitory stimuli, such as the anti-
inflammatory cytokine IL-10 or BCR-ABLTKI, which sup-
press Akt signaling, lead to activation of GSK3β and the
transcription factor MITF that drives expression of inhibi-
tory molecules such as GPNMB.
Lundberg et al. recently analysed the gene expression
profiles of commonly used in vitro DC models (moDC,
CD34+-derived Langerhans cells, CD34+-derived DC and
MUTZ-3 DC) and found MITF to be expressed >2 fold
higher in moDC as compared to each of the other in vitro
generated DC [54]. These results and own expression ana-
lyses (Figure 4) support our model in which MITF is a
relevant transcription factor in moDC. However, a func-
tion of MITF for signal transduction in human peripheral
blood DC has still to be elucidated.
A number of studies have also shown the direct influ-
ence of imatinib on T lymphocytes in vitro. Cwynarski
et al. found that this TKI inhibited T cell proliferation
and reduced the production of IFN-γ [55]. Similar re-
sults were obtained by Dietz et al.: imatinib inhibited T
cell proliferation induced by allogeneic DC [56]. A fur-
ther study found the expression of the activation
markers CD25 and CD69 as well as secretion of IL-2 to
be suppressed in activated T cells [57]. Taken together,
the direct effects of imatinib on T cells, as well as its in-
direct, mediated via DC, point to the same direction: the
inhibition of T cell function. However, the specific con-
tribution of TKI treated DC in vivo still has to be proven
and elaborated.
Our research provides an important basis for the
in vitro manipulation of moDC to induce overexpression
of GPNMB for the treatment of exaggerated immune re-
sponses. Our results might also be relevant in another
context: GPNMB is expressed at higher levels in melan-
oma and breast cancer [58]. The anti-GPNMB antibody-
drug conjugate CR011-vcMMAE (glembatumumab vedo-
tin) thus was tested for the treatment of these tumors in
phase I/II-clinical studies [59-61]. In this context, attempts
were made to increase GPNMB expression in cell lines by
treatment with various therapeutics to enhance the bind-
ing of CR011-vcMMAE. Interestingly, imatinib, as de-
scribed here for primary moDC, induced GPNMB
expression in melanoma and glioblastoma cell lines. How-
ever, the signaling mechanism was not elucidated [62]. It
remains an interesting task to investigate the expression
and function of GPNMB in other tumor entities in two re-
spects: On the one hand GPNMB is a potential tumor-
associated antigen that could be an attractive target for
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GPNMB represents a molecule that suppresses T cell re-
sponses and permits tumor escape. For both aspects, spe-
cific manipulation of GPNMB expression could be of
clinical use for the development of novel treatment ap-
proaches for malignant and autoimmune disease.
Conclusions
The results of the present study demonstrate that the im-
munosuppressive cytokine IL-10 and the therapeutically
used BCR-ABL TKI imatinib or nilotinib, examined here,
concordantly lead to dephosphorylation and thereby acti-
vation of the serine/threonine protein kinase GSK3ß via
inhibition of PI3K/Akt signaling in human moDC. This
leads to phosphorylation and translocation of MITF to the
nucleus. MITF is a transcription factor whose function in
hematopoietic and blood cells was unknown so far. Using
a small molecule inhibitor of MITF activity we confirmed
that MITF is a direct positive regulator of GPNMB ex-
pression in moDC. Moreover, treatment with BCR-ABL
TKI or PI3K/Akt inhibitors resulted in profound upregula-
tion of GPNMB that resulted in reduced stimulatory cap-
acity of moDC in MLR with allogenic T cells. This
impairment could be restored by addition of the GPNMB
Tcell ligand SD-4.
Our data extend the current understanding regarding
the molecular mechanisms that balance activating and
inhibitory signals in DC. Manipulation of the involved
signaling cascades and in particular GPNMB expression/
function may constitute a promising strategy in combin-
atory approaches using BCR-ABL TKI and DC-based
immunotherapy and may also allow for manipulation of
T cell responses in GvHD.
Methods
Generation of monocyte-derived dendritic cells (moDC)
moDC were generated ex vivo from CD14+ peripheral
blood primary monocytes that were either purified by mag-
netic cell sorting (CD14 MicroBeads, Miltenyi, Bergisch
Gladbach, Germany) or plastic adherence. Peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll/Paque
(Biochrom, Berlin, Germany) density gradient centrifuga-
tion of buffy coats obtained from healthy volunteers (Blood
Donation Center, University of Tübingen). For plastic ad-
herence cells were seeded (1 × 108/10 mL) into 75 cm2 cell
culture flasks (Corning, Cambridge, MA, USA) in serum-
free X-VIVO 20 medium (Cambrex Bio Science, Verviers,
Belgium). After 2 h of incubation at 37°C/5% CO2,
non-adherent cells were removed. The monocytes were
cultured in 10 mL RP10 medium (RPMI 1640 with
glutamax-I, supplemented with 10% inactivated fetal calf
serum, and antibiotics (Invitrogen, Karlsruhe, Germany))
supplemented with granulocyte macrophage colony-
stimulating factor (GM-CSF, 100 ng/mL; Leukine LiquidSargramostim, Sanofi, Bridgewater, USA) and IL-4
(20 ng/mL; R&D Systems, Wiesbaden, Germany) added
every 2nd day for 7 days. IL-10 (10 ng/mL; R&D Systems),
imatinib (3 μM; Cayman, Biomol, Hamburg, Germany),
nilotinib (3 μM; Cayman), Akt inhibitor MK2206 (300 nM;
Selleckchem, München, Germany), Erk inhibitor FR180204
(300 nM; Calbiochem, Merck Millipore, Darmstadt,
Germany), PI3K inhibitor LY294002 (100 nM; Cayla -
InvivoGen, Toulouse, France), c-Raf inhibitor 553003
(20 nM; Calbiochem)), MITF inhibitor ML329 (200 nM -
2000 nM in dimethyl sulfoxide (DMSO); Glixx Laborator-
ies, Southborough, MA, USA) or Kruppel-like factor 5
(KLF5) expression inhibitor CID-5951923 (2000 nM in
DMSO; Glixx Laboratories) were added starting from day
0 of cell culture every 2nd day where indicated. Maturation
was induced on day 6 by adding LPS (TLR4L, 100 ng/mL;
Sigma-Aldrich, Deisenhofen, Germany) where indicated.
After 7 days of culture, if necessary, DC-SIGN+ (CD209+)
moDC were enriched to > 90% purity prior to qRT-PCR
and western blot analyses (CD209 MicroBead Kit,
Miltenyi). Prior to lysis, purified cells were further incu-
bated for 20, 40, 60 or 90 min under the conditions that
were applied at the beginning of culture.
Quantitative reverse transcriptase PCR (qRT-PCR)
Quantification of GPNMB gene transcripts was conducted
using a LightCycler carousel-based system (Roche,
Mannheim, Germany) as described previously [20]. MITF
transcripts (all isoforms) were quantified with primers 5’-
ggagcttccaaaacaagcag-3’, 5’-acaagtgtgctccgtctcttc-3’ and
Universal ProbeLibrary probe #68 (Roche). The relative
mRNA levels were calculated as the ratio target gene/
G6PDH. For the analysis of hematopoietic and blood cells,
cell-type specific total RNA (Miltenyi) was used.
Immunostaining
moDC were stained using FITC-, PE-, PerCP-Cy5.5 or
allophycocyanin (APC) conjugated mouse monoclonal
antibodies against CD1a, CD86, CD14 (PharMingen,
Hamburg, Germany), CD80, CD83, HLA-DR, (Becton
Dickinson, Heidelberg, Germany), CD86 (PharMingen),
DC-SIGN (CD209; eBioscience, Frankfurt, Germany),
and mouse IgG isotype control (Becton Dickinson,
eBioscience). GPNMB was detected using an anti-
human GPNMB antibody (R&D Systems) conjugated
to PE (Lightning-Link R-PE conjugation kit, Innova
Bioscience, Cambrige, UK).
To exclude dead cells a viability dye (Fixable Viability
Dye eFluor 660; eBioscience) was included in all ana-
lyses. For detection of apoptosis, the Annexin V-Fluos
Staining kit (Roche) was used according to the instruc-
tions of the manufacturer. Analyses were performed on
a FACSCalibur cytometer (Becton Dickinson). Data were
analyzed using FlowJo software. The values have been
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tensity of CD209+ cells - median isotype control fluores-
cence intensity of CD209+ cells. Histogram overlays are
displayed as %Max, scaling each curve to mode = 100%.
Western blotting
If necessary, prior to lysis, positive selection of DC-SIGN
(CD209) expressing cells was conducted using the CD209
(DC-SIGN) MicroBead Kit (Miltenyi). Whole cell lysates
were prepared from moDC as described previously [20].
Separation of nuclear extract from the cytoplasmic frac-
tion was performed using the Nuclear/Cytosol Fraction-
ation Kit (BioVision; BioCat, Heidelberg, Germany). To
prevent proteolytic degradation during cell lysis, Halt
Protease and Phosphatase Inhibitor Cocktail (Fisher
Scientific, Schwerte, Germany) was added to the lysis buf-
fer. The protein levels of Akt-(P), GSK3α/β-(P) and MITF
were determined by separating 10–30 μg whole cell ly-
sates, nuclear or cytoplasmic protein fractions on a 10.5%
or 12.0% SDS-polyacrylamide gel and subsequent transfer
of protein to nitrocellulose membranes (Whatman, Dassel,
Germany). The blots were probed with the following pri-
mary antibodies: monoclonal mouse anti-human Akt
(R&D Systems), monoclonal rabbit anti-human Phospho-
Akt (Ser473), monoclonal rabbit anti-human GSK3α/β,
polyclonal rabbit anti-human Phospho-GSK3α/β (Ser 21/
9) (Cell Signaling, Frankfurt, Germany), polyclonal rabbit
anti-human MITF (abcam, Cambridge, UK) and poly-
clonal rabbit-anti-GAPDH (Merck Millipore, Darmstadt,
Germany) or monoclonal mouse-anti-GAPDH (R&D Sys-
tems). Corresponding secondary antibodies were purchased
from LI-COR Biotechnology (Bad Homburg, Germany):
IRDye 680 Donkey anti-rabbit IgG (H+ L), IRDye 680RD
Donkey anti-mouse IgG (H + L), IRDye 800CW Donkey
anti-rabbit IgG (H + L) and IRDye 800CW Donkey
anti-rabbit IgG (H + L). Different antigens were de-
tected simultaneously on the same blot using IRDye
secondary antibodies labeled with spectrally distinct
fluorescent dyes. The Odyssey Infrared Imaging System
(LI-COR Biotechnology) was used for western blot
analysis.
Mixed lymphocyte reaction (MLR)
moDC were inactivated by γ-radiation at 30 Gy, 100%,
and were seeded into 96-well microplates (Greiner
Bio-One, Frickenhausen, Germany) at concentrations of
1×104 cells/well. Blocking recombinant ligand SD-4
(R&D Systems) was added with recombinant Klotho β
(R&D Systems) serving as control. A total of 1×105
responding cells from freshly isolated allogeneic PBMC
were added to the previously prepared 1×104 stimulator
cells (moDC). Thymidine incorporation was measured on
day 5 by a 16 h pulse with [3H]thymidine (0.5 μCi
[0.0185 MBq]/well; GE Health- care, Munich, Germany).Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.Additional files
Additional file 1: Figure S1. PI3K/Akt-inhibition upregulates GPNMB
mRNA levels in human moDC. Combined analysis of different donors.
Immature moDC were generated in vitro with GM-CSF and IL-4 alone (4/GM)
or with additional Akt inhibitor MK2206 (300 nM) or Erk inhibitor FR180204
(300 nM) and analyzed for GPNMB mRNA expression by qRT-PCR. The
relative level of GPNMB mRNA in a sample was expressed as the ratio
GPNMB/G6PDH. The values were normalized to 100% for IL-4 and GM-CSF
treated moDC. Stars indicate significance (**P < .01, n.s. = not significant;
Wilcoxon matched-pairs signed rank test).
Additional file 2: Figure S2. Imatinib, nilotinib, Akt inhibitor or IL-10 inhibit
phosphorylation of Akt in human moDC. Combined analysis of different
donors. moDC were generated in vitro with GM-CSF and IL-4 alone (4/GM) or
with additional imatinib (3 μM), nilotinib (3 μM), Akt inhibitor MK2206 (300
nM) or IL-10 (10 ng/mL) and analyzed by western blotting. The relative level
of phosphorylated Akt protein (Akt-P) in a sample was expressed as the ratio
Akt-P/GAPDH (loading control). Quantitative analysis was performed using
the LI-COR Odyssey Application Software 3.0. The values were normalized to
100% for IL-4 and GM-CSF treated moDC. The mean (±SD) obtained from
measurements of different donors is shown. The raw data were used to
perform Student’s t-test (ratio paired, two-sided, equal variance). Stars
indicate significance (**P < .01, ***P < .003, n.s. = not significant).
Additional file 3: Figure S3. Imatinib, nilotonib, Akt inhibitor or IL-10
prevent phosphorylation of GSK3ß in human moDC. Combined analysis
of different donors. moDC were generated in vitro with GM-CSF and IL-4
alone (4/GM) or with additional imatinib (3 μM), nilotinib (3 μM), Akt inhibitor
MK2206 (300 nM) or IL-10 (10 ng/mL) and analyzed by western blotting. The
relative level of phosphorylated GSK3ß protein (GSK3ß-P) in a sample was
expressed as the ratio GSK3ß-P/GAPDH (loading control). Quantitative analysis
was performed using the LI-COR Odyssey Application Software 3.0. The
values were normalized to 100% for IL-4 and GM-CSF treated moDC. The
mean (±SD) obtained from measurements of different donors is shown.
The raw data were used to perform Student’s t-test (ratio paired, two-sided,
equal variance). Stars indicate significance (*P < .05, **P < .01, ***P < .003,
n.s. = not significant).
Additional file 4: Figure S4. MITF transcript levels are increased upon
treatment with imatinib, nilotinib or IL-10. Combined analysis of different
donors. Immature moDC were generated in vitro with GM-CSF and IL-4
alone (4/GM) or with additional TKI (3 μM imatinib or 3 μM nilotinib) or IL-10
and analyzed for MITF mRNA expression by qRT-PCR. The relative level of
MITF mRNA in a sample was expressed as the ratio MITF/G6PDH. The values
were normalized to 100% for IL-4 and GM-CSF treated moDC.
Additional file 5: Figure S5. MITF-Inhibition downregulates GPNMB
mRNA expression in moDC. Combined analysis of different donors.
Analysis of GPNMB mRNA levels by qRT-PCR. moDC were generated in vitro
with (A) GM-CSF, IL-4 and DMSO alone (4/GM) or with additional MITF
inhibitor ML329 (MITF-inh.; 200 nM - 2000 nM) or KLF5 expression inhibitor
CID (2000 nM) as control. (B) moDC were generated with additional IL-10
alone or together with MITF inhibitor ML329 (IL-10; MITF-inh.; 200 nM - 2000
nM) or KLF5 expression inhibitor CID (IL-10; CID 2000 nM) as control. The
relative level of GPNMB mRNA in a sample was expressed as the
ratio GPNMB/G6PDH. The values were normalized to 100% for DMSO or
DMSO/IL-10 treated moDC. The raw data were used to perform Student’s
t-test (ratio paired, two-sided, equal variance). Stars indicate significance
(*P < .05, **P < .01, ***P < .003, n.s. = not significant).
Additional file 6: Figure S6. MITF-Inhibition decreases GPNMB cell surface
protein on moDC generated with imatinib or nilotinib. moDC were generated
in vitro with GM-CSF, IL-4 and imatinib or nilotinib alone and additional MITF
inhibitor ML329 (MITF-inh.; 2000 nM) or KLF5 expression inhibitor CID (2000
nM) as control. GPNMB protein level of CD209+ moDC was analyzed by flow
cytometry. Data were analyzed using FlowJo software and histogram overlays
are displayed as %Max, scaling each curve to mode = 100%.
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moDC to induce T cell responses. Combined analysis of different
donors. moDC generated in vitro with GM-CSF and IL-4 alone (4/GM) or
with imatinib (3 μM) or Akt inhibitor MK2206 (Akt.-inh., 300 nM) were
used as stimulators in MLR with allogeneic T cells. T cell proliferation
was measured by [3H]thymidine incorporation. CCPM = corrected counts
per minute. (A) Combined analysis of 5 different donors. The values were
normalized to 100% for IL-4 and GM-CSF treated moDC. (B) Increasing
concentration (0.0 μg/mL - 20.0 μg/mL) of blocking soluble recombinant
T cell ligand SD-4 were added with recombinant Klotho β serving as
control. Combined analyses of 3 different donors. The values were
normalized to 100% for Akt inhibitor MK2206 (Akt.-inh., 300 nM) treated
moDC. The raw data were used to perform Student’s t-test (ratio paired,
two-sided, equal variance). Stars indicate significance (*P < .05, n.s. = not
significant; absolute data were analyzed using Student’s t-test (ratio paired,
one-sided, equal variance).
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